Q64729
PR
Gene name |
Tgfbr1 |
Protein name |
TGF-beta receptor type-1 |
Names |
TGFR-1, ESK2, Transforming growth factor-beta receptor type I, TGF-beta receptor type I, TbetaR-I |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:21812 |
EC number |
2.7.11.30: Protein-serine/threonine kinases |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
350-377 (Activation loop from InterPro)
Target domain |
205-495 (Protein kinase domain) |
Relief mechanism |
|
Assay |
|
Autoinhibited structure
Activated structure
1 structures for Q64729
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q64729-F1 | Predicted | AlphaFoldDB |
26 variants for Q64729
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388688798 | 60 | K>I | No | EVA | |
| rs3388671864 | 73 | L>P | No | EVA | |
| rs3388677378 | 76 | R>P | No | EVA | |
| rs3388684904 | 77 | D>H | No | EVA | |
| rs1135081942 | 90 | A>E | No | EVA | |
| rs3388684160 | 129 | V>I | No | EVA | |
| rs1134575709 | 155 | H>Y | No | EVA | |
| rs3388684668 | 169 | P>H | No | EVA | |
| rs3394331939 | 170 | F>L | No | EVA | |
| rs3388681399 | 171 | I>V | No | EVA | |
| rs3388685509 | 187 | S>T | No | EVA | |
| rs3394215256 | 198 | Q>H | No | EVA | |
| rs3394239791 | 198 | Q>L | No | EVA | |
| rs3394197995 | 199 | R>* | No | EVA | |
| rs3393701915 | 201 | I>S | No | EVA | |
| rs3388681337 | 206 | V>M | No | EVA | |
| rs3388682713 | 229 | V>D | No | EVA | |
| rs3388677392 | 276 | L>P | No | EVA | |
| rs3393701901 | 328 | A>V | No | EVA | |
| rs3388684638 | 338 | N>S | No | EVA | |
| rs3388679356 | 380 | A>G | No | EVA | |
| rs3388688749 | 400 | D>H | No | EVA | |
| rs3388688764 | 433 | P>S | No | EVA | |
| rs3388684168 | 453 | N>Y | No | EVA | |
| rs3388671883 | 488 | I>F | No | EVA | |
| rs3388670437 | 497 | Q>H | No | EVA |
No associated diseases with Q64729
1 regional properties for Q64729
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | GPCR, rhodopsin-like, 7TM | 40 - 440 | IPR017452 |
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.11.30 | Protein-serine/threonine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
14 GO annotations of cellular component
| Name | Definition |
|---|---|
| activin receptor complex | A protein complex that acts as an activin receptor. Heterodimeric activin receptors, comprising one Type I activin receptor and one Type II receptor polypeptide, and heterotrimeric receptors have been observed. |
| apical plasma membrane | The region of the plasma membrane located at the apical end of the cell. |
| basolateral plasma membrane | The region of the plasma membrane that includes the basal end and sides of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis. |
| bicellular tight junction | An occluding cell-cell junction that is composed of a branching network of sealing strands that completely encircles the apical end of each cell in an epithelial sheet; the outer leaflets of the two interacting plasma membranes are seen to be tightly apposed where sealing strands are present. Each sealing strand is composed of a long row of transmembrane adhesion proteins embedded in each of the two interacting plasma membranes. |
| caveola | A membrane raft that forms small pit, depression, or invagination that communicates with the outside of a cell and extends inward, indenting the cytoplasm and the cell membrane. Examples include flask-shaped invaginations of the plasma membrane in adipocytes associated with caveolin proteins, and minute pits or incuppings of the cell membrane formed during pinocytosis. Caveolae may be pinched off to form free vesicles within the cytoplasm. |
| cell surface | The external part of the cell wall and/or plasma membrane. |
| endosome | A vacuole to which materials ingested by endocytosis are delivered. |
| membrane | A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it. |
| membrane raft | Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| protein-containing complex | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. |
| receptor complex | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
| transforming growth factor beta ligand-receptor complex | A protein complex that is formed by the association of a TGF-beta dimeric ligand with 2 molecules of each receptor molecule, TGF-beta type I receptor and TGF-beta type II receptor. The receptor molecules may form homo- or heterodimers but only once bound by the ligand. |
16 GO annotations of molecular function
| Name | Definition |
|---|---|
| activin binding | Binding to activin, a dimer of inhibin-beta subunits. |
| activin receptor activity, type I | Combining with activin-bound type II activin receptor to initiate a change in cell activity; upon binding, acts as a downstream transducer of activin signals. |
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| growth factor binding | Binding to a growth factor, proteins or polypeptides that stimulate a cell or organism to grow or proliferate. |
| I-SMAD binding | Binding to an inhibitory SMAD signaling protein. |
| metal ion binding | Binding to a metal ion. |
| protein kinase activity | Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP. |
| protein serine/threonine kinase activity | Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate. |
| protein-containing complex binding | Binding to a macromolecular complex. |
| signaling receptor binding | Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
| SMAD binding | Binding to a SMAD signaling protein. |
| transforming growth factor beta binding | Binding to TGF-beta, transforming growth factor beta, a multifunctional peptide that controls proliferation, differentiation and other functions in many cell types. |
| transforming growth factor beta receptor activity | Combining with a transforming growth factor beta (TGFbeta) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate. |
| transforming growth factor beta receptor activity, type I | Combining with a complex of transforming growth factor beta and a type II TGF-beta receptor to initiate a change in cell activity; upon binding, acts as a downstream transducer of TGF-beta signals. |
| type II transforming growth factor beta receptor binding | Binding to a type II transforming growth factor beta receptor. |
| ubiquitin protein ligase binding | Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins. |
79 GO annotations of biological process
| Name | Definition |
|---|---|
| activin receptor signaling pathway | The series of molecular signals initiated by an extracellular ligand binding to an activin receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| angiogenesis | Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels. |
| angiogenesis involved in coronary vascular morphogenesis | Blood vessel formation in the heart when new vessels emerge from the proliferation of pre-existing blood vessels. |
| anterior/posterior pattern specification | The regionalization process in which specific areas of cell differentiation are determined along the anterior-posterior axis. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism. |
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| artery morphogenesis | The process in which the anatomical structures of arterial blood vessels are generated and organized. Arteries are blood vessels that transport blood from the heart to the body and its organs. |
| blastocyst development | The process whose specific outcome is the progression of the blastocyst over time, from its formation to the mature structure. The mammalian blastocyst is a hollow ball of cells containing two cell types, the inner cell mass and the trophectoderm. |
| cardiac epithelial to mesenchymal transition | A transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. |
| cell motility | Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another. |
| cellular response to growth factor stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus. |
| cellular response to transforming growth factor beta stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus. |
| collagen fibril organization | Any process that determines the size and arrangement of collagen fibrils within an extracellular matrix. |
| coronary artery morphogenesis | The process in which the anatomical structures of coronary arteries are generated and organized. Coronary arteries are blood vessels that transport blood to the heart muscle. |
| embryonic cranial skeleton morphogenesis | The process in which the anatomical structures of the cranial skeleton are generated and organized during the embryonic phase. |
| endothelial cell activation | The change in morphology and behavior of an endothelial cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. |
| endothelial cell migration | The orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. |
| endothelial cell proliferation | The multiplication or reproduction of endothelial cells, resulting in the expansion of a cell population. Endothelial cells are thin flattened cells which line the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium. |
| epicardium morphogenesis | The developmental process by which an epicardium is generated and organized. |
| epithelial to mesenchymal transition | A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. |
| filopodium assembly | The assembly of a filopodium, a thin, stiff protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal growth cone. |
| germ cell migration | The orderly movement of a cell specialized to produce haploid gametes through the embryo from its site of production to the place where the gonads will form. |
| heart development | The process whose specific outcome is the progression of the heart over time, from its formation to the mature structure. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood. |
| in utero embryonic development | The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus. |
| intracellular signal transduction | The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell. |
| kidney development | The process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and/or excretes the end products of body metabolism in the form of urine. |
| lens development in camera-type eye | The process whose specific outcome is the progression of the lens over time, from its formation to the mature structure. The lens is a transparent structure in the eye through which light is focused onto the retina. An example of this process is found in Mus musculus. |
| male gonad development | The process whose specific outcome is the progression of the male gonad over time, from its formation to the mature structure. |
| mesenchymal cell differentiation | The process in which a relatively unspecialized cell acquires specialized features of a mesenchymal cell. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types. |
| negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| negative regulation of chondrocyte differentiation | Any process that stops, prevents, or reduces the frequency, rate or extent of chondrocyte differentiation. |
| negative regulation of endothelial cell differentiation | Any process that stops, prevents, or reduces the frequency, rate or extent of endothelial cell differentiation. |
| negative regulation of endothelial cell proliferation | Any process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation. |
| negative regulation of extrinsic apoptotic signaling pathway | Any process that stops, prevents or reduces the frequency, rate or extent of extrinsic apoptotic signaling pathway. |
| negative regulation of miRNA transcription | Any process that stops, prevents or reduces the frequency, rate or extent of microRNA (miRNA) gene transcription. |
| nervous system development | The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state. |
| neuron fate commitment | The process in which the developmental fate of a cell becomes restricted such that it will develop into a neuron. |
| parathyroid gland development | The process whose specific outcome is the progression of the parathyroid gland over time, from its formation to the mature structure. The parathyroid gland is an organ specialised for secretion of parathyroid hormone. |
| pathway-restricted SMAD protein phosphorylation | The process of introducing a phosphate group on to a pathway restricted SMAD protein. A pathway restricted SMAD protein is an effector protein that acts directly downstream of the transforming growth factor family receptor. |
| peptidyl-serine phosphorylation | The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine. |
| peptidyl-threonine phosphorylation | The phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine. |
| pharyngeal system development | The process whose specific outcome is the progression of the pharyngeal system over time, from its formation to the mature structure. The pharyngeal system is a transient embryonic complex that is specific to vertebrates. It comprises the pharyngeal arches, bulges of tissues of mesoderm and neural crest derivation through which pass nerves and pharyngeal arch arteries. The arches are separated internally by pharyngeal pouches, evaginations of foregut endoderm, and externally by pharyngeal clefts, invaginations of surface ectoderm. The development of the system ends when the stucture it contributes to are forming: the thymus, thyroid, parathyroids, maxilla, mandible, aortic arch, cardiac outflow tract, external and middle ear. |
| positive regulation of apoptotic process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. |
| positive regulation of apoptotic signaling pathway | Any process that activates or increases the frequency, rate or extent of apoptotic signaling pathway. |
| positive regulation of cell growth | Any process that activates or increases the frequency, rate, extent or direction of cell growth. |
| positive regulation of cell migration | Any process that activates or increases the frequency, rate or extent of cell migration. |
| positive regulation of cell population proliferation | Any process that activates or increases the rate or extent of cell proliferation. |
| positive regulation of DNA-templated transcription | Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. |
| positive regulation of endothelial cell proliferation | Any process that activates or increases the rate or extent of endothelial cell proliferation. |
| positive regulation of epithelial to mesenchymal transition | Any process that increases the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition is where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. |
| positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation | Any process that activates or increases the frequency, rate or extent of epithelial to mesenchymal transition involved in endocardial cushion formation. |
| positive regulation of filopodium assembly | Any process that activates or increases the frequency, rate or extent of the assembly of a filopodium, a thin, stiff protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal growth cone. |
| positive regulation of gene expression | Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| positive regulation of MAPK cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade. |
| positive regulation of miRNA transcription | Any process that activates or increases the frequency, rate or extent of microRNA (miRNA) gene transcription. |
| positive regulation of pathway-restricted SMAD protein phosphorylation | Any process that increases the rate, frequency or extent of pathway-restricted SMAD protein phosphorylation. Pathway-restricted SMAD proteins and common-partner SMAD proteins are involved in the transforming growth factor beta receptor signaling pathways. |
| positive regulation of protein kinase B signaling | Any process that activates or increases the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B. |
| positive regulation of SMAD protein signal transduction | Any process that increases the rate, frequency or extent of SMAD protein signal transduction. Pathway-restricted SMAD proteins and common-partner SMAD proteins are involved in the transforming growth factor beta receptor signaling pathways. |
| positive regulation of stress fiber assembly | Any process that activates or increases the frequency, rate or extent of the assembly of a stress fiber, a bundle of microfilaments and other proteins found in fibroblasts. |
| positive regulation of tight junction disassembly | Any process that activates or increases the frequency, rate or extent of tight junction disassembly. |
| post-embryonic development | The process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure. See embryonic development. |
| protein autophosphorylation | The phosphorylation by a protein of one or more of its own amino acid residues (cis-autophosphorylation), or residues on an identical protein (trans-autophosphorylation). |
| protein phosphorylation | The process of introducing a phosphate group on to a protein. |
| regulation of cardiac muscle cell proliferation | Any process that modulates the frequency, rate or extent of cardiac muscle cell proliferation. |
| regulation of DNA-templated transcription | Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. |
| regulation of epithelial to mesenchymal transition | Any process that modulates the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. |
| regulation of gene expression | Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| regulation of protein binding | Any process that modulates the frequency, rate or extent of protein binding. |
| regulation of protein ubiquitination | Any process that modulates the frequency, rate or extent of the addition of ubiquitin groups to a protein. |
| response to cholesterol | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cholesterol stimulus. |
| response to estrogen | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics. |
| roof of mouth development | The biological process whose specific outcome is the progression of the roof of the mouth from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure. The roof of the mouth is the partition that separates the nasal and oral cavities. |
| signal transduction | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. |
| skeletal system development | The process whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure. The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton). |
| skeletal system morphogenesis | The process in which the anatomical structures of the skeleton are generated and organized. |
| thymus development | The process whose specific outcome is the progression of the thymus over time, from its formation to the mature structure. The thymus is a symmetric bi-lobed organ involved primarily in the differentiation of immature to mature T cells, with unique vascular, nervous, epithelial, and lymphoid cell components. |
| transforming growth factor beta receptor signaling pathway | The series of molecular signals initiated by an extracellular ligand binding to a transforming growth factor beta receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| ventricular compact myocardium morphogenesis | The process in which the anatomical structures of the compact cardiac ventricle muscle are generated and organized. |
| ventricular septum morphogenesis | The developmental process in which a ventricular septum is generated and organized. A ventricular septum is an anatomical structure that separates the lower chambers (ventricles) of the heart from one another. |
| ventricular trabecula myocardium morphogenesis | The process in which the anatomical structures of the trabecular cardiac ventricle muscle are generated and organized. |
11 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q8NER5 | ACVR1C | Activin receptor type-1C | Homo sapiens (Human) | PR |
| P36897 | TGFBR1 | TGF-beta receptor type-1 | Homo sapiens (Human) | PR |
| Q8K592 | Amhr2 | Anti-Muellerian hormone type-2 receptor | Mus musculus (Mouse) | PR |
| Q62312 | Tgfbr2 | TGF-beta receptor type-2 | Mus musculus (Mouse) | PR |
| P27040 | Acvr2b | Activin receptor type-2B | Mus musculus (Mouse) | PR |
| Q61288 | Acvrl1 | Serine/threonine-protein kinase receptor R3 | Mus musculus (Mouse) | PR |
| Q8K348 | Acvr1c | Activin receptor type-1C | Mus musculus (Mouse) | PR |
| Q5CD18 | TGFBR1 | TGF-beta receptor type-1 | Sus scrofa (Pig) | PR |
| P80201 | Acvr1 | Activin receptor type-1 | Rattus norvegicus (Rat) | PR |
| P70539 | Acvr1c | Activin receptor type-1C | Rattus norvegicus (Rat) | PR |
| P20792 | daf-1 | Cell surface receptor daf-1 | Caenorhabditis elegans | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MEAAAAAPRR | PQLLIVLVAA | ATLLPGAKAL | QCFCHLCTKD | NFTCETDGLC | FVSVTETTDK |
| 70 | 80 | 90 | 100 | 110 | 120 |
| VIHNSMCIAE | IDLIPRDRPF | VCAPSSKTGA | VTTTYCCNQD | HCNKIELPTT | GPFSEKQSAG |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LGPVELAAVI | AGPVCFVCIA | LMLMVYICHN | RTVIHHRVPN | EEDPSLDRPF | ISEGTTLKDL |
| 190 | 200 | 210 | 220 | 230 | 240 |
| IYDMTTSGSG | SGLPLLVQRT | IARTIVLQES | IGKGRFGEVW | RGKWRGEEVA | VKIFSSREER |
| 250 | 260 | 270 | 280 | 290 | 300 |
| SWFREAEIYQ | TVMLRHENIL | GFIAADNKDN | GTWTQLWLVS | DYHEHGSLFD | YLNRYTVTVE |
| 310 | 320 | 330 | 340 | 350 | 360 |
| GMIKLALSTA | SGLAHLHMEI | VGTQGKPAIA | HRDLKSKNIL | VKKNGTCCIA | DLGLAVRHDS |
| 370 | 380 | 390 | 400 | 410 | 420 |
| ATDTIDIAPN | HRVGTKRYMA | PEVLDDSINM | KHFESFKRAD | IYAMGLVFWE | IARRCSIGGI |
| 430 | 440 | 450 | 460 | 470 | 480 |
| HEDYQLPYYD | LVPSDPSVEE | MRKVVCEQKL | RPNIPNRWQS | CEALRVMAKI | MRECWYANGA |
| 490 | 500 | ||||
| ARLTALRIKK | TLSQLSQQEG | IKM |